Cambridge, Massachusetts, March 19, 2025 (Globe News) – Akebia Theraetics®Inc. (“Akebia”) AkbaAnd a vital pharmaceutical company aimed at improving the lives of people affected by kidney disease, today announced that it had started a written general show (“offer”). All shares are served by Akbia. In addition, Akebia expects that networks will give a 30 -day option to purchase an additional 15 % of their shared shares that have been sold at the offer at the public table price, and lower discounts of subscription. The offer is subject to the market and other conditions, and there can be no guarantee on whether the offer may be completed or when the offer may be completed, or with regard to the actual size or terms of the offer.
Leerink Partners and Piper Sandler & Co. As co -managed managers.
The shares are offered by Akebia according to the statement of registration of the shelf that was submitted to the Securities and Stock Exchange Committee (“SEC”) on September 3, 2024 and announced that the National Council was approved on September 12, 2024.
The display is presented only by the version bulletin and the release leaflet supplement, which is part of the rack registration statement. It is expected that a preliminary bulletin bulletin supplements are expected to be presented related to describing the conditions provided and described to SEC, and if presented, it can be obtained for free by visiting SEC on SEC on www.sec.gov. Copies of the initial version of the first version and the accompanying leaflet can also be obtained, when available, by contact: Leerink Partners LLC, attention: Syndicate DePartment, 53 State Street, 40th floor, Boston, MA 02109, by phone on (800) -808-7525, conversion. 6105, or by email on Syndicate@leerink.com; Or PIPER SANDLER & Co. , Attention: Version Bulletin section, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by phone on (800) -747-3924, or by e -mail on email Perffector@psc.com. The final conditions of the presentation will be revealed in the Appendix of the Foundation Bulletin to be presented to the Supreme Education Council.
This press statement will not constitute a offer for sale, or a request for a offer to buy these securities, and there should not be any sale of these securities in any state or jurisdiction that this offer, petition or sale will be illegal before registration or rehabilitation under the laws of securities in any state or competence of this.
About Akebia Therapeutics
Akebia Therapeutics, Inc. It is a fully integrated pharmaceutical pharmaceutical company with the purpose of improving the lives of people affected by kidney disease. Akbia was founded in 2007, based in Cambridge, Massachusetts.
Topical data
This press statement contains aspecting data in the sense submitted by the Law on Reforming for the Private Securities for the year 1995, in its amended form, which involves great risks and doubts. Terminology “expects to expect”, “insurance,” building “,” “,”, “thinking”, “follow -up”, “it is possible,” must, “designer,” appreciation, “project,” expect, “prediction,” “the future”, “strategy”, “” “” “” “” “” “” “” “” ” “” “” “” “” “” “” “” “” “” “” “” “” “” “” “” “” “” “” “” “” “”. The grant to insurance companies to buy additional shares. Actual results may differ from those expected or implicit in these aspirations. At all, you should not put an unjustified dependence on this aspiration data. Additional risks and suspicions related to shows include Akebia and its works that are specified under the title “Risk Factors” in the annual report of Akebia on the 10-K form for the fiscal year ending December 31, 2024, which is a divided Akebia completion supplements that may be presented with SEM and other capabilities that Akebia may make with SEC in the future. The aspiration data contained in this press statement (except for what is mentioned otherwise) speaks only from its date, and with the exception of what is required under the law, Akebia does not undertake, and specifically fades, i.e. commitment to updating any aspiration data contained in this press statement.
Akebia Therapeutics
Mercedes Carrasco
Mcarrasco@akebia.com
Source: Akebia Therapeutics, Inc.
© 2025 benzinga.com. Benzinga does not provide investment advice. All rights reserved.
